BMEA

In May 2026, Biomea Fusion announced poster presentations of icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions, leading to a stock price increase. In April 2026, the company announced positive 52-week results from its Phase 2 COVALENT-112 trial in Type 1 diabetes, but the stock experienced a decline. In March 2026, Biomea Fusion announced the first patient dosed in newly initiated Phase II programs enrolling Type 2 diabetes patients, resulting in a stock increase, and reported its full-year 2025 financial results. In February 2026, the stock saw an increase. In January 2026, the stock increased. An FDA clinical hold on COVALENT-111 and -112 trials was resolved in late 2024/early 2025, shifting the company's focus to clinical acceleration.